Last update 23 Jan 2025

XMVA-09

Overview

Basic Info

Drug Type
AAV based gene therapy
Synonyms
Target
Ang2 x VEGF
Mechanism
Ang2 modulators(Angiopoietin-2 modulators), VEGF modulators(Vascular endothelial growth factor modulators)
Therapeutic Areas
Congenital DisordersEye DiseasesCardiovascular Diseases+ [1]
Active Indication
Wet age-related macular degenerationDiabetic macular oedema
Inactive Indication-
Originator Organization
Hefei Xingmou Biotechnology Co., Ltd.
Active Organization
PackGene Biotech Co., Ltd.PackGene Biotech Co., Ltd.StartupHefei Xingmou Biotechnology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

3
Clinical Trials associated with XMVA-09
CTR20241282
/ Not yet recruitingPhase 1/2
一项开放、单臂、剂量递增和剂量扩展的Ⅰ/Ⅱ期临床试验评价XMVA09单次给药在湿性年龄相关性黄斑变性（wAMD）患者中的安全性、耐受性、免疫原性和有效性
[Translation] An open-label, single-arm, dose-escalation and dose-expansion Phase I/II clinical trial evaluating the safety, tolerability, immunogenicity and efficacy of a single dose of XMVA09 in patients with wet age-related macular degeneration (wAMD)
ChiCTR2400082972
/ SuspendedPhase 1/2IIT
An open-label, single-arm,single dose, dose-escalating and dose-expanding phase I/II clinical trial evaluated the safety, tolerability, immunogenicity, and efficacy of XMVA09 in subjects with wet AMD (wAMD)
ChiCTR2400085329
/ RecruitingEarly Phase 1IIT
Exploratory Clinical Study for the Safety, Tolerability, and Preliminary Efficacy of XMVA09 in the Treatment of Wet Age-Related Macular Degeneration (wAMD) Patients
100 Clinical Results associated with XMVA-09
Login to view more data
100 Translational Medicine associated with XMVA-09
Login to view more data
100 Patents (Medical) associated with XMVA-09
Login to view more data
100 Deals associated with XMVA-09
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 2
CN
Hefei Xingmou Biotechnology Co., Ltd.
12 Apr 2024
Wet age-related macular degenerationPhase 2
CN
PackGene Biotech Co., Ltd.PackGene Biotech Co., Ltd.Startup
12 Apr 2024
Diabetic macular oedemaIND Approval
CN
Hefei Xingmou Biotechnology Co., Ltd.
19 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free